본문으로 건너뛰기
← 뒤로

Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.

Cancer medicine 2025 Vol.14(23) p. e71447

Harada GK, Park J, Peterson N, Munjal A, Imagawa D, Jutric Z, Dayyani F, Valerin J, Hong DS, Seyedin SN

📝 환자 설명용 한 줄

[BACKGROUND] The relative benefit of neoadjuvant therapies remains controversial for patients with (borderline) resectable pancreatic ductal adenocarcinoma (PDAC).

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 1258
  • p-value p < 0.05
  • p-value p < 0.001

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Harada GK, Park J, et al. (2025). Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.. Cancer medicine, 14(23), e71447. https://doi.org/10.1002/cam4.71447
MLA Harada GK, et al.. "Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.." Cancer medicine, vol. 14, no. 23, 2025, pp. e71447.
PMID 41347669
DOI 10.1002/cam4.71447

Abstract

[BACKGROUND] The relative benefit of neoadjuvant therapies remains controversial for patients with (borderline) resectable pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to create a model to predict response to multiagent neoadjuvant chemotherapy (NAC) followed by radiotherapy with elective nodal irradiation (ENI).

[METHODS] Using the National Cancer Database (NCDB), we identified patients with cT1-4N0M0 PDAC diagnosed between 2006 and 2020 treated with multiagent NAC, radiation with ENI, followed by curative resection with nodal dissection. A LASSO logistic regression model was used to predict ypN0 status, with generation of a nomogram and assessment of outcomes in training and testing cohorts. Secondary endpoints of negative-margin resection and overall survival were also examined. Out-of-sample predictions were then made on a separate ENI-naïve cohort, with similar assessments of selected outcomes. The threshold for statistical significance was set to p < 0.05.

[RESULTS] A total of 1053 patients were identified with a median age of 64.0 years (IQR = 57-70 years). The final model included pancreatic body tumor location, clinical T stage, time from diagnosis to radiation therapy and surgery, ENI dose, and duration of NAC, among others. Patients predicted for treatment response were more likely to be ypN0 (71.5% vs. 29.7%, p < 0.001), had more R0 resections (87.3% vs. 62.6%, p < 0.001), and improved OS after accounting for competing risks of perioperative death (SHR = 0.64, 95% CI = 0.46-0.89, p = 0.008). A similar significant trend was noted in the ENI-naïve cohort (N = 1258). Model AUC was 0.718 and 0.725 in training and testing cohorts, respectively.

[CONCLUSIONS] Using a machine learning approach, we define a nomogram capable of predicting treatment response to multiagent NAC followed by radiotherapy with or without ENI. Patients selected by this model had higher rates of ypN0, higher R0 resection rates, and improved OS.

MeSH Terms

Humans; Middle Aged; Female; Male; Pancreatic Neoplasms; Aged; Neoadjuvant Therapy; Supervised Machine Learning; Carcinoma, Pancreatic Ductal; Lymphatic Irradiation; Nomograms; Pancreatectomy; Treatment Outcome; Antineoplastic Combined Chemotherapy Protocols